JAMPRO
30.8.2021 17:02:10 CEST | Business Wire | Press release
Jamaica’s manufacturing sector has shown resilience through the COVID-19 pandemic, with the country seeing positive developments in industries such as chemicals and cosmetics.
Manufacturers have seized new opportunities to export to markets that have experienced disruptions in their supply chains. This has led to increased production of items like cleaning chemicals, sanitizers, masks, and OTC pharmaceuticals to meet local and international demand. Jamaica expects this manufacturing expansion to contribute significantly to its economic recovery effort in the next 5 years.
These developments support the island’s goal to be a manufacturing leader in the region. Its government has long highlighted the sector as an area for growth as a myriad of possibilities exist, and Jamaica is strategically located to easily access key markets like the United States, the United Kingdom, Canada, CARICOM and Latin America.
Jamaica has one of the most diverse manufacturing sectors in the Caribbean, ranging from large food-based manufacturing giants such as GraceKennedy Limited and Jamaica Producers Group , to a burgeoning “clean beauty” industry with companies like Ettenio and Irie Rock manufacturing hair and skin care for local and international consumers.
The manufacturing of medical devices, electronics, building materials, and product fitting and assembly are other activities taking place on the island. Contract manufacturing is also an emerging area, as companies seek to use the island as their manufacturing and export base. Jamaica benefits from preferential market access to several regions through trade agreements, further strengthening its position as an ideal contract manufacturing location.
Building on this strong manufacturing tradition, Jamaica’s trade and investment promotions agency, JAMPRO , says that the stage is set for more industries to grow, even with constraints created by the pandemic.
President of JAMPRO, Diane Edwards, explained, “Jamaicans are resourceful, innovative, and committed, and because of that our manufacturing sector continues to find new ways to develop products that are in demand. There are difficulties, but there are opportunities, so the government has been working to give this sector the support it needs to thrive during the pandemic.”
At JAMPRO, this assistance has included engaging manufacturers and investors to produce more value-added goods. The organisation has ongoing initiatives that deliver business-matchmaking services, and facilitates the packaging and promotion of investment projects.
In collaboration with the Jamaica Manufacturers and Exporters Association Limited (JMEA), JAMPRO also provides education and awareness around important subjects like incentives, the Special Economic Zone (SEZ) framework, and regional and global trade agreements that are favourable for products manufactured in Jamaica. The aim is to enhance opportunities for persons to do business in the island.
Positive outlook for manufacturing
With recent global trends in nearshore manufacturing and increased consumption of goods, JAMPRO envisages that more manufacturing will be taking place in Jamaica.
Global health and lifestyle trends will fuel the production of high value goods such as Jamaican Black Castor Oil and its derivatives, and cosmetics made with natural ingredients. According to Transparency Market Research (TMR) the global cosmetics ingredients market, valued at US$30 Bn in 2020, is expected to attain a market value of US$51.6 Bn by 2030.
TMR also notes the rising popularity of natural/herbal cosmetics products, as these items are viewed as healthier alternatives. This creates an excellent opportunity for Jamaica, which currently grows several of the ingredients needed to manufacture these goods.
Reflecting on these trends, Berletta Henlon Forrester, Manager of Manufacturing and Mining at JAMPRO, stated, “Entrepreneurs can explore manufacturing beyond food and beverage, and diversify into health & beauty, packaging & paper, and household chemicals. These industries are supported by Jamaica’s capacity to provide an abundance of ingredients such as bamboo, castor, turmeric, aloe vera and cannabis, to name a few .”
To produce the ideal ecosystem for the success of the aforementioned industries, Jamaica is embarking on a National Five-Year Manufacturing Growth Strategy and is executing government reforms to improve the ease of doing business. This combination should foster the growth of manufacturing and strengthen the sector’s overall performance.
Forrester said, “This is the right time for ambitious manufacturers and investors, both large and small, to initiate their strategies towards Jamaica as the location for their manufacturing project . JAMPRO will be available, as always, to provide the necessary guidance and assistance.”
ABOUT JAMPRO
The Jamaica Promotions Corporation (JAMPRO)’s mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce.
For more information on JAMPRO, please visit https://dobusinessjamaica.com/ .
Follow us on:
Twitter
Facebook
Instagram
LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005017/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
